Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Average Rating of “Buy” by Analysts

Palvella Therapeutics, Inc. (NASDAQ:PVLA) has been given an average recommendation of “Buy” by the sixteen brokerages that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, thirteen have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $184.8667.

A number of research analysts have weighed in on the stock. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $193.00 price objective on shares of Palvella Therapeutics in a report on Tuesday, December 16th. Canaccord Genuity Group increased their target price on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. TD Cowen restated a “buy” rating on shares of Palvella Therapeutics in a research report on Monday, February 2nd. Chardan Capital restated a “buy” rating and issued a $210.00 price target on shares of Palvella Therapeutics in a research note on Monday. Finally, HC Wainwright upped their price target on Palvella Therapeutics from $200.00 to $255.00 and gave the stock a “buy” rating in a report on Tuesday, February 24th.

Insider Activity

In other Palvella Therapeutics news, Director Elaine J. Heron bought 2,400 shares of Palvella Therapeutics stock in a transaction dated Friday, February 27th. The stock was acquired at an average cost of $125.00 per share, with a total value of $300,000.00. Following the purchase, the director directly owned 47,812 shares in the company, valued at $5,976,500. This represents a 5.28% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Kathleen Goin sold 4,302 shares of the stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total value of $420,004.26. The disclosure for this sale is available in the SEC filing. Company insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Palvella Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Group One Trading LLC grew its position in shares of Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after purchasing an additional 200 shares during the period. Archer Investment Corp acquired a new position in shares of Palvella Therapeutics during the 3rd quarter worth about $28,000. Russell Investments Group Ltd. purchased a new position in Palvella Therapeutics in the 3rd quarter valued at about $36,000. China Universal Asset Management Co. Ltd. purchased a new position in Palvella Therapeutics in the 4th quarter valued at about $167,000. Finally, Police & Firemen s Retirement System of New Jersey acquired a new stake in Palvella Therapeutics in the 2nd quarter worth about $37,000. 40.11% of the stock is owned by hedge funds and other institutional investors.

Palvella Therapeutics Price Performance

PVLA opened at $126.05 on Tuesday. The firm has a fifty day moving average price of $101.50 and a 200 day moving average price of $86.93. Palvella Therapeutics has a 1 year low of $18.23 and a 1 year high of $151.18. The stock has a market cap of $1.49 billion, a P/E ratio of -47.93 and a beta of -0.31.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.